SCHEMBL4773537

SCHEMBL4773537

COC(=O)c1ccc(N(Cc2cccc(Cl)c2Cl)S(=O)(=O)N(C)C)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.51
LMNA P02545 3/20 0.51
ALDH1A1 P00352 5/20 0.47
KDM4E B2RXH2 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
THRB P10828 1/20 0.47
HTT P42858 1/20 0.47
RAB9A P51151 3/20 0.42
L3MBTL1 Q9Y468 2/20 0.42
TP53 P04637 2/20 0.41
GAA P10253 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TSHR P16473 3/20 0.41
HPGD P15428 1/20 0.40
CYP1A2 P05177 1/20 0.40
CYP2C19 P33261 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4777409 0.88 ALDH1A1 (0.51) MAPTLMNAALDH1A1KDM4EMEN1
SCHEMBL4777497 0.87 MAPT (0.49) MAPTLMNAALDH1A1KDM4EMEN1
SCHEMBL4768135 0.87 MAPT (0.49) MAPTLMNAALDH1A1KDM4EMEN1
SCHEMBL4770776 0.87 MAPT (0.46) MAPTLMNAALDH1A1KDM4EMEN1
SCHEMBL4776409 0.86 MAPT (0.48) MAPTLMNAALDH1A1KDM4EKMT2A
SCHEMBL4767972 0.85 MAPT (0.48) MAPTLMNAALDH1A1KDM4EKMT2A
SCHEMBL4775186 0.85 MAPT (0.46) MAPTLMNAALDH1A1KDM4EMEN1
SCHEMBL4775041 0.85 MAPT (0.51) MAPTLMNAALDH1A1KDM4EMEN1
SCHEMBL4775212 0.85 MAPT (0.48) MAPTLMNAALDH1A1KDM4EMEN1
SCHEMBL4768089 0.84 MAPT (0.47) MAPTLMNAALDH1A1KDM4EKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP claimed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US claimed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO claimed
EP-1942888-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Cytokinetics, Inc. (US) 2008-07-16 EP disclosed
US-20070135435-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INCORPORATED 2007-06-14 US disclosed
WO-2007056078-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INC. (US) 2007-05-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135435-A1 Certain chemical entities, compositions, and methods KIF5B, KIF2C, PLK1 MAPT 294/4885LMNA 1022/4885ALDH1A1 2159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.